![[Toyota Times] Century as a Brand, Lexus as Innovation: All the Details on Toyota's New Project!](https://businessfortnight.com/wp-content/uploads/2025/10/Toyota-Times-Century-as-a-Brand-Lexus-as-Innovation-All-218x150.jpg "[Toyota Times] Century as a Brand, Lexus as Innovation: All the Details on Toyota's New Project!")
Daix (France), Long Island City (New York, United States), October 21, 2022 – Inventiva (Euronext Paris and Nasdaq: IVA), a clinical-stage biopharmaceutical firm centered on the growth of oral small molecule therapies for the remedy of nonalcoholic steatohepatitis (NASH) and different ailments with vital unmet medical wants, at present introduced that a scientific summary has been chosen for poster presentation at the upcoming The Liver Meeting® 2022 hosted by the American Association for the Study of Liver Diseases on November 4-8, 2022 in Washington, DC.
The summary evaluates the correlation between the response to lanifibranor remedy and adiponectin ranges. Low adiponectin ranges are recognized to be related to NASH and with heart problems. Liver biomarkers and imaging assessments, in addition to adiponectin serum ranges measures, have been carried out throughout Inventiva’s NATIVE Phase IIb medical trial, as a way to consider the relation between adiponectin modifications and the enchancment of a broad panel of markers of liver and cardiometabolic well being in sufferers with NASH. The adiponectin ranges at baseline have been low in sufferers enrolled in the NATIVE medical trial, and remedy with lanifibranor considerably elevated adiponectin ranges in distinction to placebo. This enhance in adiponectin is correlated with enhancements in glycemic management, insulin resistance, lipid profile, liver checks and systemic irritation, in addition to liver steatosis quantified by ultrasound-based imaging. These knowledge additional present that lanifibranor, along with its helpful impact on liver histology, additionally improves markers of cardiometabolic well being and will increase adiponectin ranges, and thus has the potential to lower the danger for heart problems in sufferers with NASH.
The particulars of the presentation are as follows:
Abstract:
| Abstract title: | “Lanifibranor-induced improvement of liver and cardiometabolic markers of NASH is associated with an increase in adiponectin” |
| Poster quantity: | 2526 |
| Presentation sort: | Poster presentation |
| Authors: | Michael P. Cooreman, Sven Francque, Philippe Huot-Marchand, Lucile Dzen, Martine Baudin, Jean-Louis Junien, Pierre Broqua, Manal F. Abdelmalek |
| Date: | November 5, 2022 – 8:30am-5:00pm (EST) |
Inventiva may even be current with a sales space: we’re inviting you to go to us from Friday 4th via Monday 7th, throughout exhibition corridor opening hours at sales space #548 positioned in the exhibition corridor of the convention middle.
About lanifibranor
Lanifibranor, Inventiva’s lead product candidate, is an orally-available small molecule that acts to induce anti-fibrotic, anti-inflammatory and helpful vascular and metabolic modifications in the physique by activating all three peroxisome proliferator‑activated receptor (PPAR) isoforms, that are effectively‑characterised nuclear receptor proteins that regulate gene expression. Lanifibranor is a PPAR agonist that’s designed to focus on all three PPAR isoforms in a reasonably potent method, with a effectively‑balanced activation of PPARα and PPARδ, and a partial activation of PPARγ. While there are different PPAR agonists that focus on just one or two PPAR isoforms for activation, lanifibranor is the solely pan‑PPAR agonist in medical growth for the remedy of NASH. Inventiva believes that lanifibranor’s reasonable and balanced pan‑PPAR binding profile contributes to the favorable tolerability profile that has been noticed in medical trials and pre‑medical research up to now. The FDA has granted Breakthrough Therapy and Fast Track designation to lanifibranor for the remedy of NASH.
About Inventiva
Inventiva is a clinical-stage biopharmaceutical firm centered on the analysis and growth of oral small molecule therapies for the remedy of sufferers with NASH and different ailments with vital unmet medical want. The Company advantages from a robust experience and expertise in the area of compounds focusing on nuclear receptors, transcription components and epigenetic modulation. Inventiva’s lead product candidate, lanifibranor, is at the moment in a pivotal Phase III medical trial, NATiV3, for the remedy of grownup sufferers with NASH, a frequent and progressive persistent liver illness for which there are at the moment no authorised therapies.
The Company has established a strategic collaboration with AbbVie in the space of autoimmune ailments that resulted in the discovery of the drug candidate cedirogant (ABBV-157), an oral RORγ inverse agonist which is being evaluated in a Phase IIb medical trial, led by AbbVie, in grownup sufferers with reasonable to extreme persistent plaque psoriasis. Inventiva’s pipeline additionally contains odiparcil, a drug candidate for the remedy of grownup mucopolysaccharidoses (MPS) VI sufferers. As a part of Inventiva’s resolution to focus medical efforts on the growth of lanifibranor, it suspended medical efforts regarding odiparcil and is reviewing out there choices with respect to its potential additional growth. Inventiva is in the course of of choosing an oncology growth candidate for its Hippo signaling pathway program.
The Company has a scientific group of roughly 80 folks with deep experience in the fields of biology, medicinal and computational chemistry, pharmacokinetics and pharmacology, and medical growth. It owns an in depth library of roughly 240,000 pharmacologically related molecules, roughly 60% of that are proprietary, in addition to a wholly-owned analysis and growth facility.
Inventiva is a public firm listed on compartment C of the regulated market of Euronext Paris (ticker: IVA – ISIN: FR0013233012) and on the Nasdaq Global Market in the United States (ticker: IVA). www.inventivapharma.com.
Contacts
Important Notice
This press launch accommodates “forward-looking statements” inside the that means of the protected harbor provisions of the Private Securities Litigation Reform Act of 1995. All statements, aside from statements of historic details, included on this press launch are forward-looking statements. These statements embrace, however should not restricted to, forecasts and estimates with respect to Inventiva’s pre-clinical packages and medical trials, together with recruitment, screening and enrolment for these trials, together with the LEGEND trial for the remedy of NAFLD, the NATiV3 Phase III medical trial with lanifibranor in NASH, the investigator-initiated Phase II trial of lanifibranor in sufferers with NAFLD and T2D, and the anticipated Phase IIb medical trial of cedirogant led by AbbVie, potential growth of and regulatory pathway for odiparcil, medical trial knowledge releases and publications, the info, insights and impacts which may be gathered from medical trials the potential therapeutic advantages of lanifibranor usually and together with empagliflozin, the design of trials and any potential amendments to trial design, any measures to implement or to lower the display failure price or enhance the enrollment price or different meant impacts on the NATiV3 trial, and the anticipated advantages associated thereto, the Company’s settlement with Sino Biopharm, together with expectations with respect to enrollment of sufferers in Greater China in the NATiV3 trial, pipeline and preclinical and medical growth plans, milestone funds, royalties and product gross sales, potential proceeds underneath the Company’s financing preparations, future actions, expectations, plans, development and prospects of Inventiva and the sufficiency of Inventiva’s money assets and money runway. Certain of those statements, forecasts and estimates might be acknowledged by the use of phrases corresponding to, with out limitation, “believes”, “anticipates”, “expects”, “intends”, “plans”, “seeks”, “estimates”, “may”, “will”, “would”, “could”, “might”, “should”, “plans”, “designed”, “hopefully” , “target”, “aim”, and “continue” and comparable expressions. Such statements should not historic details however fairly are statements of future expectations and different forward-looking statements which are primarily based on administration’s beliefs. These statements mirror such views and assumptions prevailing as of the date of the statements and contain recognized and unknown dangers and uncertainties that would trigger future outcomes, efficiency or future occasions to vary materially from these expressed or implied in such statements. Future occasions are troublesome to foretell and should rely upon components which are past Inventiva’s management. There might be no ensures with respect to pipeline product candidates that the medical trial outcomes shall be out there on their anticipated timeline, that future medical trials shall be initiated as anticipated, that product candidates will obtain the obligatory regulatory approvals, or that any of the anticipated milestones by Inventiva or its companions shall be reached on their anticipated timeline, or at all. Actual outcomes could turn into materially totally different from the anticipated future outcomes, efficiency or achievements expressed or implied by such statements, forecasts and estimates, on account of a variety of components, together with that Inventiva is a clinical-stage firm with no authorised merchandise and no historic product revenues, Inventiva has incurred vital losses since inception, Inventiva has a restricted working historical past and has by no means generated any income from product gross sales, Inventiva would require further capital to finance its operations, Inventiva’s future success relies on the profitable medical growth, regulatory approval and subsequent commercialization of present and any future product candidates, preclinical research or earlier medical trials should not essentially predictive of future outcomes and the outcomes of Inventiva’s medical trials could not help Inventiva’s product candidate claims, Inventiva could encounter substantial delays in its medical trials or Inventiva could fail to exhibit security and efficacy to the satisfaction of relevant regulatory authorities, enrolment and retention of sufferers in medical trials is an costly and time-consuming course of and could possibly be made harder or rendered inconceivable by a number of components exterior Inventiva’s management, Inventiva’s product candidates could trigger adversarial drug reactions or produce other properties that would delay or forestall their regulatory approval, or restrict their industrial potential, Inventiva faces substantial competitors and Inventiva’s business, and preclinical research and medical growth packages and timelines, its monetary situation and outcomes of operations could possibly be materially and adversely affected by the present COVID-19 pandemic and geopolitical occasions, corresponding to the battle between Russia and Ukraine, associated sanctions and associated impacts and potential impacts on the initiation, enrolment and completion of Inventiva’s medical trials on anticipated timelines, and macroeconomic circumstances, together with international inflation and unsure monetary markets. Given these dangers and uncertainties, no representations are made as to the accuracy or equity of such forward-looking statements, forecasts and estimates. Furthermore, forward-looking statements, forecasts and estimates solely communicate as of the date of this press launch. Readers are cautioned to not place undue reliance on any of those forward-looking statements.
Please discuss with the Universal Registration Document for the 12 months ended December 31, 2021 filed with the Autorité des Marchés Financiers on March 11, 2022, the Annual Report on Form 20-F for the 12 months ended December 31, 2021 filed with the Securities and Exchange Commission on March 11, 2022 and the monetary report for the first half of 2022 to be filed Securities and Exchange Commission for added info in relation to such components, dangers and uncertainties.
All info on this press launch is as of the date of the launch. Except as required by legislation, Inventiva has no intention and is underneath no obligation to replace or evaluation the forward-looking statements referred to above.
- Inventiva – PR – AASLD Abstract – EN – 10 21 2022
